CTOs on the Move

DuPont Pioneer

www.pioneer.com

 
DuPont Pioneer headquartered in Des Moines, Iowa, is the world’s leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. DuPont Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere. Science with Service Delivering Success.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.pioneer.com
  • 7100 NW 62nd Ave
    Johnston, IA USA 50131
  • Phone: 515.270.3200

Executives

Name Title Contact Details

Similar Companies

21st Century Medicine Inc

21st Century Medicine Inc is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scios

Scios Inc. is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Magen BioSciences Inc

Magen BioSciences Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`